Free Trial
ASX:BD1

BARD1 Life Sciences (BD1) Stock Price, News & Analysis

BARD1 Life Sciences logo

About BARD1 Life Sciences Stock (ASX:BD1)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
801,545 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BARD1 Life Sciences Limited engages in the research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer to enhance patient outcomes and save lives in Australia. Its cancer diagnostics portfolio includes commercialized hTERT test used as an adjunct to urine cytology testing; and diagnostic tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The company is also providing Molecular NET technology, including its EXO-NETTM product to capture and purify exosomes. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in Notting Hill, Australia.

Receive BD1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BARD1 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

BD1 Stock News Headlines

Life Kit
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Headlines

BD1 Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that BARD1 Life Sciences investors own include Vulcan Energy Resources (VUL), Splitit Payments (SPT), Meta Platforms (META), Lake Resources (LKE), Kalium Lakes (KLL) and Collins Foods (CKF).

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.27 million
Book Value
A$0.36 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (ASX:BD1) was last updated on 1/15/2025 by MarketBeat.com Staff
From Our Partners